Medicine and Dentistry
Gastric Inhibitory Polypeptide
100%
Incretin
100%
Glucose Homeostasis
100%
Appetite
100%
Pancreatic Islet
100%
Neurotensin Receptor Agonist
100%
Glucagon Like Peptide 1
83%
Beta Cell
66%
Glucose
66%
Insulin
50%
Receptor
33%
Neurotensin
33%
Observation
16%
Cytokine
16%
Programmed Cell Death
16%
Secretion (Process)
16%
Diabetes
16%
Insulin Release
16%
Peptide
16%
Food Intake
16%
Hormone
16%
Cell Survival
16%
Glucagon Like Peptide 1 Receptor
16%
Carboxy Terminal Sequence
16%
Cell Proliferation
16%
Neurotensin Receptor
16%
Enzyme Degradation
16%
Peptide Bond
16%
Keyphrases
Glucose Homeostasis
100%
Receptor Agonist
100%
Glucagon-like
100%
Incretin Mimetics
100%
Pancreatic Function
100%
Glucose-dependent Insulinotropic Polypeptide
83%
Copyright
33%
Receptor Signaling
33%
Glucose-lowering Drugs
33%
Diabetes
16%
Food Intake
16%
Dose Effect
16%
Insulin
16%
B Cells
16%
Glucose-stimulated Insulin Secretion
16%
Induced Apoptosis
16%
Biological Action
16%
Glucose-dependent Insulinotropic Polypeptide Receptor
16%
Insulin Release
16%
Receptor Activation
16%
Insulin Concentration
16%
Secretory Activity
16%
Pancreatic β-cells
16%
β-Cell Survival
16%
Insulinotropic Effects
16%
A1 Receptor
16%
Therapeutic Potential
16%
Incretin
16%
Significant Benefit
16%
Leaner Mouse
16%
Peptide Bond
16%
Incretin Receptors
16%
β-cell Proliferation
16%
Pharmacology, Toxicology and Pharmaceutical Science
Glucose
100%
Gastric Inhibitory Polypeptide
100%
Incretin
100%
Neurotensin Receptor Agonist
100%
Glucagon-Like Peptide-1
83%
Insulin
66%
Receptor
33%
Neurotensin
33%
Mouse
16%
Cell Proliferation
16%
Apoptosis
16%
Cytokine
16%
Survival
16%
Peptide
16%
Diabetes Mellitus
16%
Enzyme
16%
Hormone
16%
Glucagon-Like Peptide 1 Receptor
16%
Leaner Mutant Mouse
16%
Peptide Bond
16%
Neurotensin Receptor
16%